2024's edition for GU Cancer Trials is here, selected by LARVOL CLIN. Based on reactions from 5,000 oncologists on X. #LARVOL #Oncology #GUCancer #CancerResearch #OncologyUpdates #CancerData #ClinicalTrials

Adjuvant IO trials in muscle-invasive urothelial carcinoma: IMvigor010: Atezo DFS HR 0.89, OS HR 0.85. CheckMate 274: Nivo DFS HR 0.71, OS HR 0.76. AMBASSADOR: Pembro DFS HR 0.73, OS HR 0.98. #oncology #cancer #urothelialcarcinoma OncoAlert Matt Galsky Tom Powles Andrea Apolo, M.D.

2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes. Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

Interesting results from KEYMAKER-U03 by Katy Beckermann Lenvatinib + belzutifan produced ORR of 47% whereas pembro + lenvatinib had ORR of 40%. Modest improvement of PFS. Lenvatinib seems to carry a lot of the benefit and toxicity of combos in this setting #ascoGU25

#GU25 highlights #CommunityOnc: 1. Radical ✂️ vs. XRT high risk PCa 2. #TALAPRO2: PARPi in M1 CRPC 3. #EnzaP: ARPi + LuPSMA in M1 CRPC 4. #NIAGARA update: Resectable MIBC 5. #EV302 update: Metastatic #BladderCancer 6. #CM9ER update: 1L mRCC #OncTwitter #gism ASCO 1/7

Delighted to share our review paper on ADCs in NSCLC with AGA is out! Very timely given the anticipated data readouts this year. Such an honour to be a part of this awesome team, special thanks to Giannis Mountzios and Jordi Remon for leading this 🙌🏻

Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers. Jyoti Malhotra JAMA Oncology 📖 DOI 👉🏻 10.1001/jamaoncol.2024.5218 #nsclc #driver #biomarkers #molecular #egfr #alk #ros1 #braf #ret #met #ntrk #kras #her2 #lcsm

🔥#CM816 Press Release: Nivolumab + chemo is the first and only neoadjuvant-only IO regimen to show a significant OVERALL SURVIVAL benefit in resectable NSCLC! Waiting for the full data to update this slide 👇🏽 Oncology Brothers OncoAlert #lcsm

Dr Amol Akhade SGBCC Hope Rugo Sara Tolaney Vinay Prasad MD MPH Timothée Olivier, MD Erika Hamilton, MD, FASCO Yakup Ergün OncoAlert On this topic, even when discussing this with our patients… I have used this table by Dr Sarah Sammons - what we have right now is iDFS.

#SGBCC2025 Optimizing axillary management. Great algorithm by Dr. Cicero Urban, informed by results from the SOUND and INSEMA trials.

What adjuvant treatment for TNBC with residual disease after KN522? 👉cape + pembro

Gastric cancer The Lancet doi.org/10.1016/S0140-… 👏Excellent and comprehensive summary from screening to targeted therapies by Raghav Sundar Lizzy Smyth Yelena Y. Janjigian MD Kohei shitara Hanneke van Laarhoven ESMO - Eur. Oncology

⚡️ Comprehensive review on perioperative management in urothelial carcinoma: - Immunotherapy & ADCs in neoadjuvant and adjuvant settings - Novel biomarkers (ctDNA, TIGIT/PD-1, DNA methylation) - Bladder-sparing approaches and quality of life considerations - Distinct

Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in Nature Cancer MarleenKokLab doi.org/10.1038/s43018…

FLAURA2 trial: Osi + CT improves PFS & OS (⬇️ 23% risk death) vs Osi alone in mEGFR NSCLC. Qx: -Intensification for all pts? Benefit in some subgroups only (Brain) -Chemo or ami for intensification?toxicity QoL, relevant for decisions -Cost -Is Osi alone no more valid? #WCLC2025

#WCLC25 Great summary by LARVOL 👇

Some key supportive care advances in Onc w/ data that improve QoL & should be part of our practice: 1. Olanzapine 2. Diclofenac & B12 for capecitabine 3. Mg for Cisplatin 4. Fezolinetant for VMS 5. Exercise 6. Cryo for neuropathy & hair loss What else wld you add #SuppOnc? 1/7

💫🌟🚨 NEW in NEJM Adjuvant Pembrolizumab vs Observation in MIUC 📘 #Alliance A031501 / #AMBASSADOR Trial 🧪 N=702 | Median follow-up: 44.8 months 🔗 nejm.org/doi/full/10.10… 🎓 Andrea Apolo, M.D., Petros Grivas, Guru P. Sonpavde, MD, Stephanie Berg, William Y. Kim, Bradley McGregor, Suzanne Cole, MD, FACP, FASCO,

PEACE-1 Trial Update: Phase III trial in de novo mCSPC: upfront abiraterone-prednisone significantly improved OS (HR=0.82). 👉Among 589 control pts, 183 crossed over to abiraterone post-progression. Adjusted HRs (RPSFTM, IPCW, TSE) remained consistent, confirming survival benefit

A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. ja.ma/4nSCh3h